Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

(2016) Matthew I. Milowsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

(2016) David Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms

(2016) M. Pinkerneil et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2015) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics

(2015) Stefan Vallo et al.   Translational Oncology

Biology of the cell cycle inhibitor p21CDKN1A: molecular mechanisms and relevance in chemical toxicology

(2014) Ilaria Dutto et al.   ARCHIVES OF TOXICOLOGY

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

(2014) Edward Sausville et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target

(2014) Y. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors

(2014) W-T Wang et al.   ONCOGENE

CHK2 kinase in the DNA damage response and beyond

(2014) L. Zannini et al.   Journal of Molecular Cell Biology

Optimal Treatment for Metastatic Bladder Cancer

(2014) Estrella M. Carballido et al.   Current Oncology Reports

EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines

(2013) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary

(2013) Hiroaki Itamochi et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

The DNA damage response and cancer therapy

(2012) Christopher J. Lord et al.   NATURE

p21 promotes error-free replication-coupled DNA double-strand break repair

(2012) Maurizio Mauro et al.   NUCLEIC ACIDS RESEARCH

Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

(2011) L. A. Parsels et al.   CLINICAL CANCER RESEARCH

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

(2011) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS